期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非酒精性脂肪性肝病治疗策略 被引量：1

下载PDF
导出
摘要 非酒精性脂肪性肝病（nonaleoholic fattv liverdisease，NAFLD）指除外酒精和其他明确的损肝因素所致的、以弥漫性肝细胞大泡性脂肪变为主要特征的临床病理综合征，包括单纯性脂肪肝以及由其演变的非酒精性脂肪性肝炎（Nonalcoholic steatohepatitis，NASH）和肝硬化。研究表明，
作者 杨兰兰 王妍
机构地区 河北大学护理学院 河北医科大学第二医院消化内科
出处 《河北职工医学院学报》 2008年第6期74-77,共4页 Journal of Hebei Medical College for Continuing Education
关键词 非酒精性脂肪性肝病 肝病治疗 非酒精性脂肪性肝炎 单纯性脂肪肝 病理综合征 脂肪变 大泡性 肝细胞
分类号 R575.5 [医药卫生—消化系统] R657.3 [医药卫生—外科学]
  • 相关文献

参考文献28

  • 1张莉,贾继东.非酒精性脂肪肝的发病机制与药物治疗进展[J].临床药物治疗杂志,2005,3(4):21-23. 被引量：7
  • 2Alllerioan Gastmenterol Association. American Gastroenterological Association medical position statement:nonalcoholic fatty liver disease [ J ]. Gastroenterology. 2002, 123 (5) : 1702-1704
  • 3Angulo P. GI Epidemiology: nonalcoholic fatty liver disease [ J ]. Aliment Pharmacol Ther. 2007,25 (8) : 883-889
  • 4Archerwr,Lamarche B,Deriazo,et al.Variations in body composition and plasma lipids in response to a high-carbohydrate diet[ J ].ObesRes, 2003,11 (8) : 978-986
  • 5Hatzitolios A,Savopoulos C,Lazarakig,et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liverdiseasewith dyslipidemia [J]. Indian J gastroentero, 2004,23 : 131-134
  • 6Neuschwander-Tetri BA,Brunt EM,Wehmeier KR,et al. Improved non-alcoholic steatohepatitis after 48 weeks of treatment with the PPAR2-gamma ligand rosiglitazone [Jl. Hepatology, 2003,10:1008-1017
  • 7Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis[J]. N Engl J Med, 2006,355 : 2297-2307
  • 8May LD,Lefkowitch JH,Kram MT,et al.Mixed hepatocellular cholestatic liver injury later pioglitazone therapy[J]. Ann Intern Med,2002,136:449-452
  • 9Uygun A,Kadayifcia,Isik AT,et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis [J]. Aliment Pharmacol Ther 2004,19 : 537-544
  • 10Bugianesi E,Gentileore E,Manini R. et al. A randomized controlled trial of meiformin versus vitamin E or preseriptive diet in nonaleolic fatty liver dlisease [J]. Am J Gastroenterol, 2005,100(5 ) : 1052-1090

二级参考文献60

共引文献96

同被引文献30

  • 1刘梅,陆伦根.非酒精性脂肪性肝病的治疗策略[J].临床消化病杂志,2007,19(4):204-206. 被引量：6
  • 2Day CP,James OF. Steatohepatitis:a tale of two "hits"? Gas- troenterology, 1998,114(4) :842-845.
  • 3Shyangdan D,Clar C,Ghouri N,et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic re- view. Health Technol Assess,2011,15(38 ) : 100-110.
  • 4Stein LL,Dong MH,Loomba R. Insulin sensitizers in nonalco- holic fatty liver disease and steatohepatitis:Current status. Adv Ther, 2009,26( 10 ) : 893-907.
  • 5Martin CK,Redman LM,Zhang J,et al. Lorcaserin,a 5-HT (2C) receptor agonist,reduces body weight by decreasing ener- gy intake without influencing energy expenditure. J Clin En- doerinol Metab,2011,96(3) : 837-845.
  • 6Fidler MC,Sanchez M,Raether B,et al. A one-year random- ized trial of lorcasefin for weight loss in obese and overweight adults:the BLOSSOM trial. J Clin Endocrinol Metab,2011,96 ( 10) : 3067-3077.
  • 7O'Neil PM,Smith SR,Weissman NJ,et al. Randomized place- bo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus:tbe BLOOM-DM study. Obesity (Silver Spring), 2012,20(7): 1426-1436.
  • 8Nelson A,Torres DM,Morgan AE,et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis:A randomized placebo-controlled trial. J Clin Gastroenterol, 2009,43 (10) : 990-994.
  • 9Georgescu EF. Angiotensin receptor blockers in the treatment of NASH/NAFLD:Could they be a first-class ption? Adv Ther, 2008,25 ( 11 ) : 1141-1174.
  • 10Yoshiji H,Kuriyama S,Yoshij J,et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis devel- opment in rats. Hepatology,2001,34(4 Pt 1 ) :745-750.

引证文献1

二级引证文献4

河北职工医学院学报
2008年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部